GS Paper - 2 (Diseases)

The COVID-19 Working Group of the NTAGI has recommended inclusion of the Serum Institute's Covovax in the national vaccination programme for those aged 12 years and above, official sources said on 3 March 2022. India's drug regulator had approved Covovax for restricted use in emergency situations in adults and in the 12-17 age groups, subject to certain conditions.

What

  1. The COVID-19 Working Group has now recommended to the Standing Technical Sub-Committee of the National Technical Advisory Group on Immunisation (NTAGI) that Covovax be included in the national vaccination programme for those aged 12 years and above.
  2. A meeting of the COVID-19 Working Group of the NTAGI took place on 1 April 2022 during which data of Covovax was reviewed, after which it recommended that the vaccine can be included in the national COVID-19 vaccination programme for inoculating those aged 12 years and above.
  3. India began inoculating children aged 12-14 from March 16. Biological E's Corbevax is being used to inoculate them.